Replimune's FDA date passed with no decision. Silence is not a signal.

The FDA's goal date for deciding on Replimune's RP1 in advanced melanoma was Sunday, 2 August. It passed. As of Tuesday the agency had still not acted, and the stock — up more than 120% across three sessions after a favorable advisory committee vote — is now trading on an absence.

An absence is the most misread object in biotech. It's worth being precise about what a missed decision date tells you, and what it doesn't.

A PDUFA date is a goal, not a deadline

PDUFA is the Prescription Drug User Fee Act, the arrangement under which drug companies pay fees and the FDA commits to review timelines in return. The "PDUFA date" everyone circles on a calendar is the agency's own goal date for taking an action on an application. It is a performance target the FDA sets for itself. It is not a statutory deadline, and nothing happens to the agency or to the application when one slips.

So the honest read of 2 August passing is narrow: the review isn't finished, or it is finished and the announcement isn't. Silence is not evidence of approval and it is not evidence of rejection.

You will hear that a late decision means the company and the agency are negotiating a label. You will also hear that it means another rejection is coming. Neither has anything behind it. That retail commentary is currently split between exactly those two readings is a decent illustration of what a genuinely uninformative event looks like.

The panel voted on a narrower question than the headline

On 30 July, the FDA's cellular, tissue and gene therapies advisory committee voted 10-3 in Replimune's favor. The question it answered was whether the registrational IGNYTE trial was "evaluable and clinically meaningful" — not whether the drug should be approved. Advisory committees advise. The FDA is not bound by them.

The agency's own reviewers had gone in hard, and their objections are the substance of this decision:

• IGNYTE had no concurrent control group, which in the reviewers' words makes a survival claim "not an evidence-based claim."
• The individual contributions of RP1 and of nivolumab to patient responses can't be separated.
• The response assessments themselves were called "unreliable and difficult to interpret."

None of that is new. This is the third pass at the same application. Replimune received complete response letters in July 2025 and again on 10 April 2026, both citing trial design. A complete response letter is the FDA saying it cannot approve the application in the form submitted — a rejection of the filing, not necessarily a verdict on the drug.

The number the argument is about

From the company's own three-year analysis presented at ASCO in May: an objective response rate of 33.6%, median duration of response of 24.8 months, median overall survival of 32.9 months, and 47.8% of treated patients alive at three years.

Translated: in patients whose melanoma had already progressed on anti-PD-1 therapy, that share saw their tumors shrink by the threshold the trial defined, and those responses held for roughly two years on median. In a population that has run out of options, that is a real result.

Now the limit, which is the part the FDA keeps returning to. Every one of those figures comes from a trial in which nobody was randomized to anything else. There is no arm to compare against, so there is no way to establish how many of those patients would have responded to nivolumab alone, or how long a similar group would have survived without RP1. More follow-up doesn't fix this. The missing arm is missing permanently.

What accelerated approval would actually be

If RP1 clears, it clears through accelerated approval — granted on a surrogate measure, in this case tumor response, with the confirming evidence owed later. The confirmatory study is IGNYTE-3, which randomizes patients against physician's choice of treatment, enrolls roughly 400 patients, and has overall survival as its primary endpoint. Those survival data are expected in 2030.

So the question being argued over this week gets settled around the end of the decade. In the interval, a positive decision puts the drug on the market and lets the company sell it. That is the trade accelerated approval makes, and it is worth understanding before treating an approval as the end of the story rather than a provisional milestone with a date attached.

Will they run out of money first?

Replimune held $268.9 million in cash, cash equivalents and short-term investments as of 31 March 2026, and said that funds operations into the first quarter of calendar 2027 — a figure that already includes scale-up for a potential launch.

Read the two together. Even the good outcome lands the company a few quarters short of the end of its own stated runway, with a commercial launch to fund from there. Approval would improve the terms of a raise. It would not remove the need for one.

The bad outcome isn't hypothetical here either. When the first complete response letter arrived in July 2025, the stock fell 64%. Same drug, same trial, same regulator, opposite direction. A binary that has already re-rated this company hard once is the argument for doing the work before the date rather than reacting after it.

What to watch

• The decision itself, and if it's an approval, the label — the population it covers is what determines the commercial size, not the fact of approval.
• If it's a third complete response letter: whether the FDA names a path this time, or repeats that the trial can't support the filing. Those are very different outcomes for the same headline.
• The terms of the next financing. A raise into an approval and a raise into a rejection are not the same transaction.
• IGNYTE-3 enrollment progress, since that trial is now the whole evidentiary backstop.

The portable lesson is about the calendar. Retail investors treat a PDUFA date as a scheduled event with a scheduled answer, which is why an empty date generates so much noise. It is a goal date on a review that either finished or didn't. When one passes quietly, the correct update to your view is close to zero — and knowing that is worth more than any interpretation of the silence.

This is analysis, not investment advice. It describes what has been disclosed and what has not, and does not recommend any position in any security.